IGHE and allergic bronchopulmonary aspergillosis: A recent article investigating the immunological mechanism and efficacy of omalizumab in the treatment of ABPA found that this agent not only reduces FcεR1 and IgE attachment on the surface of basophilic granulocytes but also reduces their susceptibility and maximal responsiveness to Aspergillus fumigatus.